Literature DB >> 7803368

Light, melatonin and the sleep-wake cycle.

G M Brown1.   

Abstract

Blood levels of the pineal hormone melatonin are high at night and low during the day. Its secretion is regulated by a rhythm-generating system located in the suprachiasmatic nucleus of the hypothalamus, which is in turn regulated by light. Melatonin is regulated not only by that circadian oscillator but acts as a darkness signal, providing feedback to the oscillator. Melatonin has both a soporific effect and an ability to entrain the sleep-wake rhythm. It also has a major role in regulating the body temperature rhythm. Melatonin rhythms are altered in a variety of circadian rhythm disorders. Melatonin treatment has been reported to be effective in treatment of disorders such as jet lag and delayed sleep phase syndrome.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7803368      PMCID: PMC1188623     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  90 in total

1.  Bright light induction of strong (type 0) resetting of the human circadian pacemaker.

Authors:  C A Czeisler; R E Kronauer; J S Allan; J F Duffy; M E Jewett; E N Brown; J M Ronda
Journal:  Science       Date:  1989-06-16       Impact factor: 47.728

2.  Transition between advance and delay responses to eastbound transmeridian flights.

Authors:  A Gundel; H M Wegmann
Journal:  Chronobiol Int       Date:  1989       Impact factor: 2.877

3.  Biological effects of morning-plus-evening bright light treatment of seasonal affective disorder.

Authors:  N E Rosenthal; R G Skwerer; D A Sack; C C Duncan; F M Jacobsen; L Tamarkin; T A Wehr
Journal:  Psychopharmacol Bull       Date:  1987

4.  The antidepressant effect of light in seasonal affective disorder of childhood and adolescence.

Authors:  W A Sonis; A M Yellin; B D Garfinkel; H H Hoberman
Journal:  Psychopharmacol Bull       Date:  1987

5.  Synchronisation of a disturbed sleep-wake cycle in a blind man by melatonin treatment.

Authors:  J Arendt; M Aldhous; J Wright
Journal:  Lancet       Date:  1988-04-02       Impact factor: 79.321

6.  Alterations in nocturnal serum melatonin levels in humans with growth and aging.

Authors:  F Waldhauser; G Weiszenbacher; E Tatzer; B Gisinger; M Waldhauser; M Schemper; H Frisch
Journal:  J Clin Endocrinol Metab       Date:  1988-03       Impact factor: 5.958

Review 7.  Pharmacology and function of melatonin receptors.

Authors:  M L Dubocovich
Journal:  FASEB J       Date:  1988-09       Impact factor: 5.191

8.  Dual receptor regulation of cyclic nucleotides: alpha 1-adrenergic potentiation of vasoactive intestinal peptide stimulation of pinealocyte adenosine 3',5'-monophosphate.

Authors:  C L Chik; A K Ho; D C Klein
Journal:  Endocrinology       Date:  1988-04       Impact factor: 4.736

9.  2-[125I]iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution.

Authors:  M J Duncan; J S Takahashi; M L Dubocovich
Journal:  Endocrinology       Date:  1988-05       Impact factor: 4.736

10.  Increase in plasma melatonin, beta-endorphin, and cortisol after a 28.5-mile mountain race: relationship to performance and lack of effect of naltrexone.

Authors:  R J Strassman; O Appenzeller; A J Lewy; C R Qualls; G T Peake
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

View more
  26 in total

Review 1.  Melatonin and its receptors: a new class of sleep-promoting agents.

Authors:  Karl Doghramji
Journal:  J Clin Sleep Med       Date:  2007-08-15       Impact factor: 4.062

Review 2.  An integrative review of sleep for nutrition professionals.

Authors:  Devon L Golem; Jennifer T Martin-Biggers; Mallory M Koenings; Katherine Finn Davis; Carol Byrd-Bredbenner
Journal:  Adv Nutr       Date:  2014-11-14       Impact factor: 8.701

Review 3.  Treating Circadian Rhythm Disruption in Bipolar Disorder.

Authors:  Alexandra K Gold; Gustavo Kinrys
Journal:  Curr Psychiatry Rep       Date:  2019-03-02       Impact factor: 5.285

4.  Blue-hazard-free Candlelight OLED.

Authors:  Jwo-Huei Jou; Meenu Singh; Yu-Ting Su; Shih-Hao Liu; Zhe-Kai He
Journal:  J Vis Exp       Date:  2017-03-19       Impact factor: 1.355

Review 5.  Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

Review 6.  Tasimelteon: first global approval.

Authors:  Sohita Dhillon; Madeleine Clarke
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

7.  The 1.25 A crystal structure of sepiapterin reductase reveals its binding mode to pterins and brain neurotransmitters.

Authors:  G Auerbach; A Herrmann; M Gütlich; M Fischer; U Jacob; A Bacher; R Huber
Journal:  EMBO J       Date:  1997-12-15       Impact factor: 11.598

Review 8.  Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.

Authors:  Akshay Shetty; Jennifer W Hsu; Paul P Manka; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2018-08-18       Impact factor: 3.199

9.  Use of slow-release melatonin in treatment-resistant depression.

Authors:  E J Dalton; D Rotondi; R D Levitan; S H Kennedy; G M Brown
Journal:  J Psychiatry Neurosci       Date:  2000-01       Impact factor: 6.186

10.  Analysis of the mechanism by which melatonin inhibits human eosinophil peroxidase.

Authors:  T Lu; S Galijasevic; I Abdulhamid; H M Abu-Soud
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.